Registration
 
All news
Top Stories
Editors' Picks
Crypto News
Financial News
Currencies
Market Voices
Billionaires
Companies
Regulators News
Eugene Komchuk
Eugene Komchuk

Urogen Pharma milestone: First patient treated with new cancer medication

Urogen Pharma milestone: First patient treated with new cancer medication
@UroGenPharma: Urogen Pharma patient milestone

Urogen Pharma has taken a significant step in the treatment of bladder cancer by administering its novel medication to the first patient at Astera Urology. This marks a milestone in their ongoing efforts to provide innovative solutions for adults suffering from recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

The advancement reflects Urogen Pharma's commitment to addressing critical unmet medical needs through cutting-edge research and development. Dr. Adam Berman was instrumental in administering this pioneering treatment, potentially paving the way for further advancements in cancer therapeutics in the future.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

How precious-metals mining revival is reshaping portfolios in 2026
  • By Ciaran Ryan
  • 17 hours ago
How precious-metals mining revival is reshaping portfolios in 2026
Editors' Picks
Bitcoin price prediction after CPI rise: Is BTC headed for deeper losses?
  • By Mikhail Vnuchkov
  • 21 hours ago
Bitcoin price prediction after CPI rise: Is BTC headed for deeper losses?
Editors' Picks
Five years with Bitcoin: How El Salvador changed after legalizing BTC
  • By Eugene Komchuk
  • Yesterday
Five years with Bitcoin: How El Salvador changed after legalizing BTC
Editors' Picks
All Editors' Top Picks

Latest UroGen News

UroGen Pharma stock consolidates near weekly lows with mild gains after conference event update
  • By Ezequiel Gomes
  • 08.06.2026
UroGen Pharma stock consolidates near weekly lows with mild gains after conference event update
Companies
#UroGen
UroGen Pharma edges higher to $27.07 ahead of Goldman Sachs healthcare chat, UroGen Pharma
  • By Jainam Mehta
  • 08.06.2026
UroGen Pharma edges higher to $27.07 ahead of Goldman Sachs healthcare chat, UroGen Pharma
Companies
#UroGen
Veteran cancer researcher Mark joins Urogen Pharma to drive progress in urologic oncology
  • By Andreas Kristo
  • 25.03.2026
Veteran cancer researcher Mark joins Urogen Pharma to drive progress in urologic oncology
Companies
#UroGen
All UroGen News
  • Ciaran Ryan
  • 17 hours ago
How precious-metals mining revival is reshaping portfolios in 2026
  • Mikhail Vnuchkov
  • 21 hours ago
Bitcoin price prediction after CPI rise: Is BTC headed for deeper losses?
  • Eugene Komchuk
  • Yesterday
Five years with Bitcoin: How El Salvador changed after legalizing BTC
  • Anastasiia Chabaniuk
  • 09.06.2026
Crypto on the court: How NBA Finals became a showcase for Ledger
  • Johnathan Maverick
  • 08.06.2026
How to build wealth from scratch in 3 practical steps
  • Olga Shendetskaya
  • 15 min ago
Home rents in China’s major cities climb for third consecutive month, Michael Pettis notes
  • Parshwa Turakhiya
  • 35 min ago
SpaceX valuation climbs from $1 billion to $1.77 trillion in 16 years, Jon Erlichman notes
  • Artem Shendetskii
  • 1 hour ago
Tren Griffin: SpaceX sets IPO price at $135 a share, aiming to raise $75 billion
  • Jose Antonio Gastelum
  • 1 hour ago
Sui DeFi to enable 24/7 Asian equity trading, Adeniyi Abiodun notes
  • Daria Chernytska
  • 1 hour ago
Ethereum will not reach zero today, Wendy O notes
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.
Top News
  • Ivan Andriyenko
  • 15 hours ago
U.S. gas exports gain ground in India as Gulf supplies falter
U.S. gas exports gain ground in India as Gulf supplies falter
  • Parshwa Turakhiya
  • 17 hours ago
Japan crypto bill moves closer to final passage
Japan crypto bill moves closer to final passage
  • Igor Krasulya
  • 18 hours ago
Inflation pressure pushes ECB toward rate hike
Inflation pressure pushes ECB toward rate hike
  • Eugene Komchuk
  • 18 hours ago
Police investigate Bithumb chief over hiring of lawmaker's son
Police investigate Bithumb chief over hiring of lawmaker's son
  • Andrey Mastykin
  • 20 hours ago
U.S. strikes on Iran send Wall Street futures higher
U.S. strikes on Iran send Wall Street futures higher
Live News
  • Anton Kharitonov
  • Now
Google doubles down on AI amid stock pressure and regulatory risks
  • Anton Kharitonov
  • Now
Microsoft breaks support as pressure on shares intensifies
  • Mykhailo Ihnatenko
  • Now
Silver rebounds as Middle East tensions revive safe-haven demand
  • Anton Kharitonov
  • Now
Apple remains under pressure despite strong fundamentals
  • Mykhailo Ihnatenko
  • Now
AI stocks face first major liquidity test
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org World Association of News Publishers https://gdpr.eu/ GDPR